VERACYTE, INC. (VCYT) Form 10-Q — Jul 31, 2026
Veracyte reported strong second quarter 2026 results with revenue increasing 15% year-over-year to $150.3 million, driven primarily by a 19% jump in testing revenue. The company swung to a net profit of $25.5 million, or $0.32 per share, reversing a net loss of $980,000 in the prior-year period, reflecting improved operational leverage and expense reallocation. Research and development expenses surged 81% due to the reclassification of software development costs to align with product objectives, while general and administrative expenses declined 15% due to lower professional fees and expense reallocation.
Key figures
- Eps
- 0.32
- Revenue
- 150321000
- Net Income
- 25490000
- Revenue Yoy
- 15%
- Shares Outstanding
- 80390731
- Testing Revenue Growth
- 19%
- Total Test Volume Growth
- 13%
Price after filing
Close on the filing date to close N calendar days later (from $55.71). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.